Skip to main content
Clinical Trials/NCT02821169
NCT02821169
Completed
Phase 3

Impact of Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain in the Setting of Endoscopic Sinonasal Surgery.

University Hospital, Lille1 site in 1 country184 target enrollmentApril 1, 2015

Overview

Phase
Phase 3
Intervention
saline solution 0.9%
Conditions
Pain
Sponsor
University Hospital, Lille
Enrollment
184
Locations
1
Primary Endpoint
Visual analog scale
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

Endoscopic sinus surgery (ESS) is a prevalent surgical procedure. It is required in many chronic rhinosinusitis for whom the medical treatment failed. In order to improve the postoperative management of patients treated with ESS, we aim to assess the analgesic action of local injection of ropivacaine in the nasal fossa.

Detailed Description

A prospective randomized double blind placebo controlled study was designed. Local injection of ropivacaine or placebo was conducted at the end of the surgical procedure in both nasal fossa through endoscopic view in the sphenopalatine region. Pain was measured in the postoperative course with visual analogic scale in the recovery room and the rhinologic department.

Registry
clinicaltrials.gov
Start Date
April 1, 2015
End Date
June 1, 2019
Last Updated
4 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital, Lille
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • patients requiring endoscopic sinus surgery
  • ASA score 1 or 2
  • patients with health care insurance
  • approved consent

Exclusion Criteria

  • any sinonasal malignant tumor
  • renal failure, hepatic disorder, respiratory deficiency, cardiovascular diseases
  • neurologic disorders
  • alcohol or drugs addiction
  • preoperative facial pain from an extranasal origin
  • coagulation disorders
  • antidepressive treatment

Arms & Interventions

saline solution 0.9%

injection of saline solution in the sphenopalatine area in both nasal fossa

Intervention: saline solution 0.9%

ropivacaine (2mg/ml)

injection of ropivacaine in the sphenopalatine area in both nasal fossa

Intervention: ropivacaine

Outcomes

Primary Outcomes

Visual analog scale

Time Frame: at the 2 postoperative hours

Measure the intensity pain, in the group treated with Ropivacaine.

Secondary Outcomes

  • Analgesics consumption orally(during the 7 days post-surgery)
  • Administration of analgesics by parenteral route(at the 2 postoperative hours)
  • Visual analog scale for the during postoperative pain(At Morning and evening between the 1 and 7 days post surgery)
  • Visual analog scale for the intensity postoperative pain(at the 4 and at the 6 postoperative hours)

Study Sites (1)

Loading locations...

Similar Trials